Stay updated on Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.

Latest updates to the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedRevision: v3.4.2 added; prior notice about government funding status (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check43 days agoChange DetectedA site-wide notice about government funding status and NIH Clinical Center operations was added, and the page now shows a revision update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check50 days agoChange DetectedThe updates are minor editorial changes to UI text and versioning, including adding a 'Show glossary' option, correcting capitalization in labels such as 'Last Update Submitted that met QC Criteria' and 'No FEAR Act Data', and updating the revision from v3.3.4 to v3.4.0.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed. No changes to study content or page functionality.SummaryDifference0.0%

- Check86 days agoChange DetectedAdded a comprehensive Locations section listing participating states for the Cypress-1 trial (rev. v3.3.3).SummaryDifference2%

Stay in the know with updates to Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.